Organisation paid for research Program year 2024 Source: CMS Open Payments

Associated Retina Consultants Ltd

Neither a doctor nor a teaching hospital

Research payments

$245,595

38 payments

Through program year 2024, Associated Retina Consultants Ltd is reported as receiving $245,595 in research payments, across 38 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $49,437 6
2023 Research $46,120 4
2022 Research $67,941 15
2021 Research $19,033 1
2020 Research $29,714 3
2019 Research $33,350 9

Breakdown

Who paid Research payments · program years 2019–2024
  1. Biogen, Inc. $50,415 4 payments
  2. Genentech, Inc. $49,437 6 payments
  3. Boehringer Ingelheim International GmbH $45,733 2 payments
  4. Apellis Pharmaceuticals, Inc. $35,133 5 payments
  5. Novartis Pharmaceuticals Corporation $31,747 3 payments
  6. Regeneron Pharmaceuticals, Inc. $9,925 2 payments
  7. Janssen Research & Development, LLC $7,668 4 payments
  8. Mylan Inc. $7,245 4 payments
  9. Allergan Inc. $6,340 6 payments
  10. Boehringer Ingelheim Pharma GmbH & Co.KG $1,931 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. Mad to Assess the Safety Tolerability and PK PD in Namd Patients $49,344 5 payments
  2. SRD MRD IIa $45,754 3 payments
  3. Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) $35,363 3 payments
  4. Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $35,133 5 payments
  5. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $20,133 2 payments
  6. Preclinical Research: NSR-XLRP-OS1 $15,052 1 payment
  7. A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $11,614 1 payment
  8. Study to Determine Presence of Genetically Confirmed CNGA3- and CNGB3-Associated Achromatopsia Patients at Investigational Sites for Potential Participation in Future Clinical Research Studies $7,668 4 payments
  9. A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema $7,245 4 payments
  10. A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy $6,925 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record